A presenter during the AMCP Nexus 2019 meeting said value considerations should begin early in the development cycle, and should even continue post-launch using real-world studies.
“Right now, we need to start addressing the shift from volume to value,” Optum Life Sciences’ Sara Rivera said during the presentation. “Rather than concentrating on the number of treatments we’re putting out, [we should focus on] what’s the quality we’re putting out and how valuable is that. Payers are increasingly expecting life sciences firms to quantify the product’s value in terms that are well-defined and measurable with clinical outcomes.”
To read more, click here.